Economy/Home · Economy

Whail Pharmaceutical to Raise 10 Billion Won via Third-Party allotment Capital Increase... Entire Allocation to Pharma & Bio New Technology Fund

Whail Pharmaceutical has decided on a 10 billion won third-party allotment capital increase to secure operating funds. Whail Pharmaceutical held a board meeting on the 15th and passed a resolution to issue 1,379,690 new shares of common stock. The new share issue price is 7,248 won per share, throu

Oseong Kwon
Staff Reporter
5 min read
Whail Pharmaceutical to Raise 10 Billion Won via Third-Party allotment Capital Increase... Entire Allocation to Pharma & Bio New Technology Fund
CBC News

Whail Pharmaceutical has decided on a 10 billion won third-party allotment capital increase to secure operating funds.

Whail Pharmaceutical held a board meeting on the 15th and passed a resolution to issue 1,379,690 new shares of common stock. The new share issue price is 7,248 won per share, through which the company plans to raise a total of 9,999,993,120 won. The raised funds will be used entirely as operating funds.

The third-party allotment recipient is the Pharma & Bio New Technology Fund. The fund will receive the entire allocation of 1,379,690 new shares. The company stated that it selected the allotment recipient at the board meeting after comprehensively considering the achievement of management objectives, satisfaction of requirements as a qualified investment target, and payment capacity. The new shares will be subject to a full one-year lock-up at the Korea Securities Depository.

The Pharma & Bio New Technology Fund is a newly formed fund established in September 2026 with two investors. The largest investor is Dynamic Solution, which holds a 100% stake, while Eastgate Investment serves as the representative partner and executing partner.

Regarding the schedule, the payment date is December 30, and the new shares are scheduled to be listed on January 25, 2027. The company stated that the schedule related to this capital increase may change depending on consultations with relevant institutions.

The raised operating funds are expected to be used in the order of 1 billion won in 2026, 4 billion won in 2027, and 5 billion won in 2028 and thereafter.

Meanwhile, on the same day, Whail Pharmaceutical appointed Yoo Chul-ho, an inside director of Dynamic Solution, as a managing director (gyeongyeong jibae-in). The company explained that the purpose of the appointment is 'management of the company's overall operations during the process of a change in the largest shareholder.' The term runs from September 15, 2026, until a new management team is appointed at an extraordinary general shareholders' meeting. Yoo, as managing director, will carry out the company's overall internal and external management affairs pursuant to Article 10 of the Commercial Act, and the place where the managing director will operate is Whail Pharmaceutical.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.